A Randomized, Open-label Pilot Trial to Evaluate the Safety and Efficacy of Carmustine Wafer in Combination With Retifanlimab and Standard Radiation With or Without Temozolomide in Newly-Diagnosed Adult Subjects With Glioblastoma

Inclusion Criteria: * Newly-diagnosed adults with WHO (World Health Organization) Grade IV Glioblastoma or gliosarcoma based on histopathological or molecular criteria who had carmustine wafers placed at resection * No prior treatment for GBM other than surgical resection and carmustine wafer placement (Patients who had a biopsy prior to resection are allowed) * Post-operative MRI or CT scan within 72 hours (preferably 24 hours) of surgical resection * Substantial recovery from surgical resection * On a stable or decreasing dose of steroids * Karnofsky Performance Status of ≥ 60 * Clinically…